SCHEMBL6929244

SCHEMBL6929244

N#Cc1ccccc1Oc1ccccc1CC1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.43
SLC6A4 P31645 6/20 0.43
SLC6A2 P23975 4/20 0.43
HTR1A P08908 4/20 0.40
ADRA2A P08913 4/20 0.40
ADRA2B P18089 4/20 0.40
ADRA2C P18825 4/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
HRH1 P35367 1/20 0.38
SLC6A3 Q01959 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KCNH2 Q12809 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16825233 0.83 SLC6A4 (0.51) GBA1SLC6A4SLC6A2SLC6A3
SCHEMBL6926391 0.83 SLC6A4 (0.54) GBA1SLC6A4SLC6A2HTR1ASLC6A3
SCHEMBL6929247 0.82 GBA1 (0.51) GBA1SLC6A4SLC6A2HTR1APOLB
SCHEMBL6928757 0.81 AR (0.53) SLC6A4SLC6A2HTR1ASLC6A3KCNH2
SCHEMBL6927183 0.80 SLC6A4 (0.44) GBA1SLC6A4SLC6A2HTR1ASLC6A3
SCHEMBL6926480 0.79 HTR1A (0.58) GBA1SLC6A4SLC6A2HTR1AADRA2A
SCHEMBL3251596 0.79 SLC6A2 (0.50) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL7526768 0.79 SLC6A4 (0.56) GBA1SLC6A4SLC6A2HTR1AHRH1
SCHEMBL6927113 0.78 HRH1 (0.54) GBA1SLC6A4SLC6A2HTR1AADRA2A
SCHEMBL6927391 0.78 SLC6A4 (0.48) GBA1SLC6A4SLC6A2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6518284-B2 For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) 2003-02-11 US claimed
US-20020038031-A1 New 4 - substituted piperidines ORJALES VENERO AURELIO (ES) 2002-03-28 US claimed
EP-1002794-A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) 2000-05-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038031-A1 New 4 - substituted piperidines ADRA2C, ADRB2, ADRB1 GBA1 1368/4885SLC6A4 11/4885SLC6A2 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.